NGM Biopharmaceuticals Inc.

07/22/2021 | Press release | Distributed by Public on 07/22/2021 14:09

NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration